These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 27893470)

  • 1. The Association Between Out-of-Pocket Costs and Adherence to Adjuvant Endocrine Therapy Among Newly Diagnosed Breast Cancer Patients.
    Farias AJ; Hansen RN; Zeliadt SB; Ornelas IJ; Li CI; Thompson B
    Am J Clin Oncol; 2018 Jul; 41(7):708-715. PubMed ID: 27893470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer.
    Farias AJ; Du XL
    J Clin Oncol; 2017 Jan; 35(1):86-95. PubMed ID: 28034069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of state parity laws on copayments for and adherence to oral endocrine therapy for breast cancer.
    Chin AL; Bentley JP; Pollom EL
    Cancer; 2019 Feb; 125(3):374-381. PubMed ID: 30566762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors Associated with Adherence to Adjuvant Endocrine Therapy Among Privately Insured and Newly Diagnosed Breast Cancer Patients: A Quantile Regression Analysis.
    Farias AJ; Hansen RN; Zeliadt SB; Ornelas IJ; Li CI; Thompson B
    J Manag Care Spec Pharm; 2016 Aug; 22(8):969-78. PubMed ID: 27459660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to Adjuvant Endocrine Therapy in Insured Black and White Breast Cancer Survivors: Exploring Adherence Measures in Patient Data.
    Sheppard VB; He J; Sutton A; Cromwell L; Adunlin G; Salgado TM; Tolsma D; Trout M; Robinson BE; Edmonds MC; Bosworth HB; Tadesse MG
    J Manag Care Spec Pharm; 2019 May; 25(5):578-586. PubMed ID: 31039059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant therapy use among Appalachian breast cancer survivors.
    Tan X; Marshall VD; Anderson RT; Donohoe J; Camacho F; Balkrishnan R
    Medicine (Baltimore); 2015 Jul; 94(26):e1071. PubMed ID: 26131828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant Endocrine Therapy in Patients with Ductal Carcinoma In Situ: A Population-Based Retrospective Analysis from 2005 to 2012 in the National Cancer Data Base.
    Flanagan MR; Rendi MH; Gadi VK; Calhoun KE; Gow KW; Javid SH
    Ann Surg Oncol; 2015 Oct; 22(10):3264-72. PubMed ID: 26202556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases.
    Lambert-Côté L; Bouhnik AD; Bendiane MK; Bérenger C; Mondor M; Huiart L; Lauzier S
    Breast Cancer Res Treat; 2020 Apr; 180(3):777-790. PubMed ID: 32086655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initiation and adherence to adjuvant endocrine therapy among urban, insured American Indian/Alaska Native breast cancer survivors.
    Emerson MA; Achacoso NS; Benefield HC; Troester MA; Habel LA
    Cancer; 2021 Jun; 127(11):1847-1856. PubMed ID: 33620753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five-Year Adjuvant Endocrine Therapy Adherence Trajectories Among Women With Breast Cancer: A Nationwide French Study Using Administrative Data.
    Lailler G; Memoli V; Le Bihan Benjamin C; Ben Diane MK; Lauzier S; Mancini J; Bousquet PJ; Bouhnik AD
    Clin Breast Cancer; 2021 Aug; 21(4):e415-e426. PubMed ID: 33745868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between financial burden and adjuvant hormonal therapy adherence and persistent use for privately insured women aged 18-64 years in BCBS of Texas.
    Kim J; Rajan SS; Du XL; Franzini L; Giordano SH; Morgan RO
    Breast Cancer Res Treat; 2018 Jun; 169(3):573-586. PubMed ID: 29423900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Racial differences in long-term adjuvant endocrine therapy adherence and mortality among Medicaid-insured breast cancer patients in Texas: Findings from TCR-Medicaid linked data.
    Farias AJ; Wu WH; Du XL
    BMC Cancer; 2018 Dec; 18(1):1214. PubMed ID: 30514270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are breast cancer patients with suboptimal adherence to cardiovascular treatment more likely to discontinue adjuvant endocrine therapy? Competing risk survival analysis in a nationwide cohort of postmenopausal women.
    Artignan J; Capmas P; Panjo H; Constantinou P; Pelletier-Fleury N
    BMC Med; 2023 Nov; 21(1):463. PubMed ID: 38001491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer.
    Sedjo RL; Devine S
    Breast Cancer Res Treat; 2011 Jan; 125(1):191-200. PubMed ID: 20495864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Endocrine Therapy Initiation Timeliness With Adherence and Continuation in Low-Income Women With Breast Cancer.
    Sood N; Liu Y; Lian M; Greever-Rice T; Lucht J; Schmaltz C; Colditz GA
    JAMA Netw Open; 2022 Aug; 5(8):e2225345. PubMed ID: 35921108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors Influencing Adherence to Adjuvant Endocrine Therapy After Breast Cancer Surgery.
    Johnsson A; von Wachenfeldt A
    Cancer Rep (Hoboken); 2024 Aug; 7(8):e2160. PubMed ID: 39158164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Previous Medication Regimen Factors and Bipolar and Psychotic Disorders on Breast Cancer Endocrine Therapy Adherence.
    Haskins CB; Neuner JM; McDowell BD; Carnahan RM; Fiedorowicz JG; Wallace RB; Smith BJ; Chrischilles EA
    Clin Breast Cancer; 2020 Jun; 20(3):e261-e280. PubMed ID: 32139273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of patient race and geographical factors on initiation and adherence to adjuvant endocrine therapy in medicare breast cancer survivors.
    Camacho FT; Tan X; Alcalá HE; Shah S; Anderson RT; Balkrishnan R
    Medicine (Baltimore); 2017 Jun; 96(24):e7147. PubMed ID: 28614244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early-stage breast cancer.
    Hershman DL; Tsui J; Meyer J; Glied S; Hillyer GC; Wright JD; Neugut AI
    J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25349080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Patient Reimbursement Timing and Patient Out-of-Pocket Expenses on Medication Adherence in Patients Covered by Private Drug Insurance Plans.
    Després F; Forget A; Kettani FZ; Blais L
    J Manag Care Spec Pharm; 2016 May; 22(5):539-47. PubMed ID: 27123915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.